Prelude Therapeutics gets FDA clearance to start Phase 1 trial of PRT13722 for HR+ breast cancer

Prelude Therapeutics Inc

FDA cleared IND for PRT13722, an oral KAT6A selective degrader, for HR+/HER2- breast cancer.
Phase 1 study expected to begin enrolling patients in Q4 2026.
Study will evaluate PRT13722 as monotherapy and in combination with endocrine and targeted therapies in adults with locally advanced or metastatic HR-positive, HER2-negative breast cancer.
Company believes selective KAT6A degradation may improve efficacy and hematological safety vs dual KAT6A/B inhibitors.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.